Warner Chilcott, Mylan Deal OK'd In Birth Control IP Row

Law360, New York (August 5, 2013, 8:37 PM EDT) -- A New Jersey federal judge Monday greenlighted a settlement agreement between pharmaceutical giant Warner Chilcott Co. LLC and generics maker Mylan Inc. in Warner Chilcott’s suit over Mylan’s plans for a generic version of its birth control drug Loestrin.

The defendants have agreed that their plans to sell a generic version of Warner Chilcott’s Loestrin would infringe the claims it had asserted against them over U.S. Patent Number 5,552,394, U.S. District Judge Joel A. Pisano said in his order.

The company had accused Mylan of submitting...
To view the full article, register now.

UK Financial Services

UK Financial Services

Read Our Latest UK Financial Services Coverage

Financial Services Law360 UK provides breaking news and analysis on the financial sector. Coverage includes UK and European Union policy, enforcement, and litigation involving banks, asset management firms, and other financial services organizations.